Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Metastatic malignancies

Propper DJ, Macaulay V, O Byrne KJ, Braybrooke JP, Wilner SM, Ganesan TS, Talbot DC, Harris AL (1998) A phase II study of bryostatin 1 in metastatic malignant melanoma. Br J Cancer 78 1337-1341... [Pg.87]

Robinson, W.A., T.I. Mughal, M.R. Thomas, M. Johnson, and R.J. Spiegel, Treatment of metastatic malignant melanoma with recombinant interferon alpha 2. Immunobiology, 1986. 172(3-5) 275-82. [Pg.177]

Falkson, C.I., J. Ibrahim, J.M. Kirkwood, A.S. Coates, M.B. Atkins, and R.H. Blnm, Phase HI trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma an Eastern Cooperative Oncology Group study. J Clin Oncol, 1998.16(5) 1743-51. [Pg.177]

H. Other considerations Interferon alfa-2a has been designated an orphan drug product for the treatment of chronic myelogenous leukemia, AIDS-related Kaposi s sarcoma, renal cell carcinoma, metastatic malignant melanoma, and esophageal and colorectal cancer. [Pg.192]

Permanent hypothyroidism associated with vitiligo was reported in a woman treated with interleukin-4 for metastatic malignant melanoma (SEDA-20, 336). [Pg.612]

Kunz M, Koczan D, Ibrahim S, Gillitzer R, Gross G, Thiesen H. Differential expression of thrombospondin 2 in primary and metastatic malignant melanoma. Acta Derm Venereol 2002 82 163-169. [Pg.215]

This novel -emitting potential anti-tumor drug49fM97 359 for metastatic malignant diseases has been obtained495,496 from the 6-chloromercury derivative (equation 227), involving reduction, phosphorylation and hydrolysis. [Pg.498]

Bar MH, Snzol M, Atkins MB, et al. Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine activated killer cells. J Clin Oncol 1990 8 1138-47. [Pg.778]

Shin DM, Fossella FV, Umsawasdi T, et al. 1995. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 76 2230-2236. [Pg.329]

Floxuridine is a pyrimidine analogue that is used in regional arterial chemotherapy for primary and metastatic malignancies, delivered using an implantable pump. [Pg.1376]

Doxorubicin-resistant tumors Eungal infections Lymphomatous meningitis Metastatic malignant uveal melanoma Ovarian cancer Advanced cancer Various tumors Advanced cancer... [Pg.4]

Letellier S, Gamier JP, Spy J, Bousquet B. Determination of the L-DOPA/L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma. J Chromatogr B Biomed Sci Appl 1997 696 9-17. [Pg.1071]

Figure 4.2 Variation of retention time of l-DOPA as a function of pH of the mobile phase. As the pH increases, the retention time of l-DOPA decreases. NE, norepinephrine E, epinephrine DA, dopamine DHBA, internal standard. Reprinted from Journal of Chromatography B, 696, Letellier S, Gamier JP, Spy J, Bousquet B. Determination of the L-DOPA/L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma, pages 9-17, Copyright 1997, with permission from Elsevier... Figure 4.2 Variation of retention time of l-DOPA as a function of pH of the mobile phase. As the pH increases, the retention time of l-DOPA decreases. NE, norepinephrine E, epinephrine DA, dopamine DHBA, internal standard. Reprinted from Journal of Chromatography B, 696, Letellier S, Gamier JP, Spy J, Bousquet B. Determination of the L-DOPA/L-tyrosine ratio in human plasma by high-performance liquid chromatography. Usefulness as a marker in metastatic malignant melanoma, pages 9-17, Copyright 1997, with permission from Elsevier...
UI may present in the setting of concurrent, seemingly unrelated illnesses. New-onset UI may be the initial manifestation of certain systemic illnesses such as diabetes meUitus, metastatic malignancies, multiple sclerosis, and other neurologic illnesses. Central nervous system disease, or injury above the level of the pons, generally results in symptoms of bladder overactivity and UUI. Spinal cord injury or disease may manifest as bladder overactivity and UUI or as overflow incontinence, depending on the spinal level and completeness of the injury or disease. [Pg.1551]

O Day SJ, Agarwala SS, Naredi P, Kass CL, et al. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma a detailed safety analysis. Melanoma Res 2003 13 307-311. [Pg.2539]

FIGURE 4.22 Epithelioid angiosarcoma is potentially confused diagnostically with metastatic malignant melanoma or poorly differentiated carcinoma in the soft tissues. [Pg.113]

Fetsch PA, Marincola FM, Filie A, et al. Melanoma-associated antigen recognized by T-cells (MART-1) The advent of a preferred immunocytochemical antibody for the diagnosis of metastatic malignant melanoma with fine needle aspiration. Cancer. 1999 87 37-42. [Pg.129]

King R, Busam K, Rosai J. Metastatic malignant melanoma resembling malignant peripheral nerve sheath tumor Report of 16 cases. Am J Surg Pathol. 1999 23 1499-1505. [Pg.133]

Selby WL, Nance KV, Park KH. Carcinoembryonic antigen— immunoreactivity in metastatic malignant melanoma. Mod Pathol. 1992 5 415-419. [Pg.200]

Plaza JA, Sustet S, Petez-Montiel D. Exptession of immunohistochemical matkets in ptimaty and metastatic malignant melanoma a compatative study in 70 patients using a tissue microattay technique. Appl Immunohistochem Mol Morphol. 2007 15 421-425. [Pg.204]

S-100 may be part of a panel when considering a metastatic malignant melanoma however, sustentacular cells in the adrenal medulla are also positive for this marker. Additionally, HMB-45, which is known to be positive in malignant melanomas, is occasionally positive in pheochromocytomas. 9262... [Pg.316]

Gaber AO, Rice P, Eaton C, et al. Metastatic malignant disease of unknown origin. Am J Surg Pathol. 1983 145 493-497. [Pg.461]

FIGURE 21.14 Metastatic malignant melanoma. (A) FNA cytology of an axillary mass. (B) Pleural effusion. [Pg.908]

Morse, M. A., R. E. Coleman, G. Akabani, N. Niehaus, D. Coleman, and H. K. Lyerly. 1999. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res 59 56-58. [Pg.108]

Genentech (2007) A study of the safety and pharmacokinetics of GDC-0152, administered intravenously to patients with locally advanced or metastatic malignancies. http //clinical-trialsfeeds.org/clinical-trials/show/NCT00977067. [Pg.103]

See other pages where Metastatic malignancies is mentioned: [Pg.41]    [Pg.687]    [Pg.239]    [Pg.29]    [Pg.160]    [Pg.137]    [Pg.41]    [Pg.29]    [Pg.153]    [Pg.205]    [Pg.120]    [Pg.732]    [Pg.434]    [Pg.1208]    [Pg.5]    [Pg.798]    [Pg.90]    [Pg.206]    [Pg.206]    [Pg.207]   
See also in sourсe #XX -- [ Pg.68 ]



SEARCH



Malignancy

Malignant

Malignant disease metastatic

Metastatic malignant melanoma

© 2024 chempedia.info